Judge agreed to delay bellwether trial picks for 60 days, but ordered Horizon Therapeutics to turn over all raw clinical trial data to plaintiffs, who indicate the drug manufacturer's science was flawed.
Drug maker's motion for a 60 day extension in their deadline for selecting Tepezza hearing loss lawsuits is being opposed by plaintiffs, who turned in their bellwether selections on time on March 1.
Another four Tepezza hearing loss bellwether selections are scheduled to be submitted by defendants by April 1, and the court will randomly select another four, for a total of 12 cases that will go through case-specific discovery.
A status report on Tepezza lawsuits is due on January 5, and will update the judge on the continuing preparations for early hearing loss litigation test trials.
Texas woman left with permanent hearing loss from Tepezza indicates in a recently filed lawsuit that the maker of the thyroid eye disease drug should have recommended audiological exams and monitoring during treatments.
Following case-specific discovery in an initial pool of 12 claims involving hearing problems from Tepezza, parties will select four lawsuits that will be eligible for the first bellwether trials in the federal multidistrict litigation (MDL).
Report decribes a patient who suffered diabetic ketoacidosis that was likely caused by side effects of Tepezza, leading researchers to warn that the thyroid eye disease drug could pose serious risks for diabetes patients
Former users allege that Horizon Therapeutics was aware of long-term Tepezza hearing complaints years before a warning label update in July 2023
The deal seeks to prevent Amgen from leveraging its near-monopoly on Tepezza and other Horizon drugs into an overwhelming competitive advantage.
Manufacturer of the thyroid eye disease drug indicates it plans to move to dismiss any Tepezza lawsuits over hearing loss on federal preemption grounds, seeking to delay the work up of individual cases for potential bellwether trials.
